Johnson & Johnson Recalls Eprex Anemia Drug
Johnson & Johnson is recalling about 200,000 syringes of Eprex, an anemia drug sold wholesale and in pharmacies. Some batches of the drug may not be potent enough, health regulators are warning.
The recall affects products in 17 countries, including the U.K and Canada. No adverse events have been tied to the issue, J&J says. The manufacturer assumes that the prefilled syringes have already been used, since they were delivered to the market quite a while ago. There are around 6,300 syringes unaccounted for.
A routine internal quality analysis found that a number of the syringes contained Eprex that was either above or below the required potencies. Eprex, which is sold in the United States under the brand name Procrit, is primarily used to help anemic chronic kidney disease patients avoid blood transfusions.
This is the latest in a long string of manufacturing issues for J&J, which has also had to recall defective hip replacements, hundreds of millions of dollars of consumer medicines, contact lenses, and schizophrenia drugs.
No related posts.